A comparative pharmacokinetic study of doxorubicin and 4'-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure
- PMID: 10789596
- DOI: 10.1097/00001813-200002000-00010
A comparative pharmacokinetic study of doxorubicin and 4'-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure
Abstract
Antraquinone glycosides are an important class of antineoplastic drugs, frequently used for treatment of a variety of malignancies in children. Doxorubicin (Dox) is the most frequently used drug within this class of antineoplastics. 4'-epi-doxorubicin (Epi), a Dox isomer, was developed with the aim of reducing risks for fatal heart toxicity observed with Dox. The aim of the present study was to investigate the pharmacokinetics of Dox and Epi in children with acute lymphocytic leukemia. In total 31 patients (13 females and 18 males; median age 5.4 years; range 0.73-15.3 years) were studied using a simplified sampling procedure. The pharmacokinetic differences of the two drugs were established by their simultaneous administration. The plasma pharmacokinetics of neither Dox nor Epi correlated with the age of the patients. There were no gender differences in dose-normalized maximum concentrations of neither Dox nor of Epi. The inter-patient variation of the dose-normalized maximum concentrations of Dox and Epi is larger among females than among males. The Cmax ratio Dox/Epi was 1.39+/-0.19 (mean +/- SD). The pharmacokinetic differences of Dox and Epi in children, although less pronounced than in adults, are still of a magnitude that might be of clinical importance.
Similar articles
-
Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.Cancer Chemother Pharmacol. 1989;24(4):225-9. doi: 10.1007/BF00257622. Cancer Chemother Pharmacol. 1989. PMID: 2752502
-
Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study.Med Pediatr Oncol. 2002 May;38(5):329-37. doi: 10.1002/mpo.10052. Med Pediatr Oncol. 2002. PMID: 11979457 Clinical Trial.
-
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.J Clin Oncol. 1988 Mar;6(3):517-26. doi: 10.1200/JCO.1988.6.3.517. J Clin Oncol. 1988. PMID: 3162516
-
[Iodo-doxorubicin, a new anthracycline derivative. Current state of progress].Onkologie. 1990 Oct;13(5):346-51. doi: 10.1159/000216794. Onkologie. 1990. PMID: 2082229 Review. German.
-
Epirubicin. Clinical pharmacology and dose-effect relationship.Drugs. 1993;45 Suppl 2:20-30. doi: 10.2165/00003495-199300452-00005. Drugs. 1993. PMID: 7693418 Review.
Cited by
-
Pharmacokinetics and drug dosing in obese children.J Pediatr Pharmacol Ther. 2010 Apr;15(2):94-109. J Pediatr Pharmacol Ther. 2010. PMID: 22477800 Free PMC article.
-
Imaging of early modification in cardiomyopathy: the doxorubicin-induced model.Int J Cardiovasc Imaging. 2013 Oct;29(7):1459-76. doi: 10.1007/s10554-013-0248-0. Epub 2013 Jun 7. Int J Cardiovasc Imaging. 2013. PMID: 23744127 Review.
-
Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.Biol Sex Differ. 2018 Aug 29;9(1):38. doi: 10.1186/s13293-018-0198-2. Biol Sex Differ. 2018. PMID: 30157941 Free PMC article. Review.
-
Effect of obesity on the pharmacokinetics of drugs in humans.Clin Pharmacokinet. 2010;49(2):71-87. doi: 10.2165/11318100-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20067334 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
